Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2025)

Vivos Therapeutics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $442000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $442000.0 for Q4 2025, up 206.94% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 125.3% YoY), and the annual figure for FY2025 was $1.3 million, up 125.3%.
  • Depreciation & Amortization (CF) for Q4 2025 was $442000.0 at Vivos Therapeutics, up from $384000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $442000.0 in Q4 2025 to a low of $41000.0 in Q1 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $172000.0 (2022), against an average of $195613.6.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 76.84% in 2022, then skyrocketed 326.83% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $168000.0 in 2021, then grew by 0.6% to $169000.0 in 2022, then fell by 11.83% to $149000.0 in 2023, then fell by 3.36% to $144000.0 in 2024, then skyrocketed by 206.94% to $442000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $442000.0, $384000.0, and $306000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.